Meeting
2020 ASCO Virtual Scientific Program
Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors.
Authors
Anthony W. Tolcher
NEXT Oncology, San Antonio, TX
Anthony W. Tolcher , Raghad Karim , Yuefen Tang , Hengbang Wang , Jiao Ji , Jason Chen , Angela Kaiser , Piyush Sheladia , Mohammad Ahmad , ZHIYAN LIANG , Dajun Yang , Yifan Zhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03611868
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3512)
DOI
10.1200/JCO.2020.38.15_suppl.3512
Abstract #
3512
Poster Bd #
242
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
First Author: Meredith McKean
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2023 ASCO Annual Meeting
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.
First Author: Montaser F. Shaheen
Poster
2022 ASCO Annual Meeting
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
First Author: Nong Xu